PENNVAX

PENNVAX is a DNA vaccine developed by Inovio Pharmaceuticals, often in collaboration with academic institutions such as the University of Pennsylvania, Emory University, Duke University, and the University of Massachusetts. It is designed as a preventive and therapeutic vaccine primarily targeting Human Immunodeficiency Virus (HIV). The vaccine aims to induce broad immune responses, including antibody and T-cell responses, against multiple HIV strains (multi-clade, multi-antigen). It is typically delivered using Inovio's CELLECTRA electroporation technology to enhance its efficacy. The development of PENNVAX has been supported by significant grants from organizations like the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).

Brand names

PENNVAX-B

Other names

PENNVAX HIV vaccine